CN105147676A - Medicine for preventing or treating dental ulcer - Google Patents
Medicine for preventing or treating dental ulcer Download PDFInfo
- Publication number
- CN105147676A CN105147676A CN201510500362.1A CN201510500362A CN105147676A CN 105147676 A CN105147676 A CN 105147676A CN 201510500362 A CN201510500362 A CN 201510500362A CN 105147676 A CN105147676 A CN 105147676A
- Authority
- CN
- China
- Prior art keywords
- medicine
- lycospidinea
- day
- ulcer
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medicine, and in particular relates to a medicine for preventing or treating dental ulcer; the medicine consists of a compound Lycospidine A and accessories; the medicine is disclosed for the first time, and the medicine, since the framework type is completely new and the activity on treating dental ulcer is strong, has substantive distinguishing features; and meanwhile, the medicine obvious makes a significant progress in treatment of dental ulcer.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind for the treatment of or preventing canker sore medicine and application thereof.
Background technology
Recurrent oral ulceration is modal disease in diseases of oral mucosa.The first place of prevalence office diseases of oral mucosa.Sircus (1975) investigates 1587 people, and prevalence is 20%.As can be seen here, oral ulcer patient is a very huge colony.The cause of disease of recurrent oral ulceration is complicated, still indefinite so far, may be relevant with the factor such as the endocrine regulation of viral infection, bacteriological infection and body, immune dysfunction.The primary treatment measure of oral ulcer comprises topical therapeutic and whole body therapeutic, and because topical therapeutic toxic and side effects is lower, the people therefore obtaining people can.Although the buccal tablets that the local that occurs in recent years uses carries, easy to use, mouthfeel and compliance better, as lysozyme buccal tablet, watermelon crystal buccal tablet, cydiodine etc., these medicines emphasize particularly on different fields in sterilization, antiinflammatory, pain relieving etc.
The compound L ycospidineA that the present invention relates to is one and delivers (Jin-TangCheng in 2013, etal., LycospidineA, LycospidineA, aNewTypeofLycopodiumAlkaloidfromLycopodiumcomplanatum.Or ganicLetters, 2013, 15 (10): 2438 – 2441.) noval chemical compound, this compound has brand-new framework types, current purposes is anti-senile dementia effect (Jin-TangCheng only, etal., LycospidineA, LycospidineA, aNewTypeofLycopodiumAlkaloidfromLycopodiumcomplanatum.Or ganicLetters, 2013, 15 (10): 2438 – 2441.), the purposes of the LycospidineA that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public.
Summary of the invention
The object of the invention is to not find that it has the present situation of the report for the treatment of or preventing canker sore according in existing LycospidineA research, provide the application of LycospidineA in preparation treatment or preventing canker sore medicine.
A kind for the treatment of or preventing canker sore medicine, be made up of compound L ycospidineA and adjuvant, described compound L ycospidineA structure is as shown in formula I:
Formula I.
Described treatment or preventing canker sore medicine, adjuvant is dextrin or starch.
Described treatment or the application of preventing canker sore medicine in preparation treatment or preventing canker sore medicine.
The purposes of the LycospidineA that the present invention relates in preparation treatment or preventing canker sore medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment or preventing canker sore active strong, possess outstanding substantive distinguishing features, to be used for the treatment of or preventing canker sore obviously has significant progress simultaneously.
Detailed description of the invention
The preparation method of compound L ycospidineA involved in the present invention is see document (Jin-TangCheng, etal., LycospidineA, LycospidineA, aNewTypeofLycopodiumAlkaloidfromLycopodiumcomplanatum.Or ganicLetters, 2013,15 (10): 2438 – 2441.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound L ycospidineA tablet involved in the present invention:
Get 5 g of compound LycospidineA and add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound L ycospidineA capsule involved in the present invention:
Get 5 g of compound LycospidineA and add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
The experimental study of test example 1:LycospidineA anti-oral ulcer
1, test objective: manufacture Oral ulcer model with phenol, gives the LycospidineA of Oral ulcer model rat certain number of times every day, and whether observe LycospidineA has the effect reducing ulcer.
2, test medicine and reagent: cydiodine (Beijing Sihuan Medicine Science and Technology Co., Ltd); Phenol; Animal: Wistar rat, male, body weight 240 ~ 280g, Nanjing Medical University's Experimental Animal Center.
3, test method: get rat 50, male, body weight 240 ~ 280g, 10% chloral hydrate anesthesia, dosage: 0.35ml/100g, after anesthesia, plastic dropper (internal diameter: the 3mm) lower end of 90% phenol cotton balls being flat on rats with left bicker is about on the cheek film at 1mm place, calcination 30min, namely sees the white infringement of this place about 3mm.Divide into groups immediately after 24 hours, often organize 10, divide 5 groups, i.e. model group (adjuvant 4 times/day, not drug containing); LycospidineA high dose group (4 times/day, 0.5mg/ time); Dosage (4 times/day, 0.1mg/ time) in LycospidineA; LycospidineA low dose group (4 times/day, 0.02mg/ time) (by the preparation of above-described embodiment 1 method); Positive controls: cydiodine group (4 times/day, 0.5mg/ time).LycospidineA and cydiodine buccal tablet pulverize before use, administration is degree of being with flap coverage.Successive administration 5 days, after the front and each administration of administration, next day observes ulcer area size (diameter in ulcer) and ulcer healing situation (being considered as healing without macroscopic ulcer), and first administration is recorded as 1,2,3,4,5,6 day respectively to last administration.Ulcer area size t checks, and ulcer healing rate X2 checks.
4, result of the test: ulcer area compares (table 1): LycospidineA high dose group compares with model group, plays off-test on the 3rd day from administration, and corresponding every day compares significant difference; Cydiodine group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; In LycospidineA, dosage group compares with model group, within the 3rd day, plays off-test from administration, and corresponding every day compares significant difference; LycospidineA low dose group compares with model group, within the 5th day, plays off-test from administration, and corresponding every day compares significant difference; In LycospidineA, dosage group compares with cydiodine group, within the 1st day, plays off-test from administration, and corresponding every day compares significant difference.
Table 1 is on the impact of rat ulcer area
Note: compare with model group, * p<0.05, * p<0.01.
Healing rate (table 2): model group and LycospidineA low dose group play off-test on the 1st day from administration, and ulcer does not heal; And LycospidineA high dose group was from administration the 4th day, just there is ulcer healing, to off-test, reach 90%; Cydiodine group, from administration the 4th day, has ulcer healing, to off-test, reaches 60%; In LycospidineA, dosage group was from administration the 5th day, had ulcer healing, to off-test, reached 40%.
Table 2 is on the impact of rat ulcer healing time
Note: compare with model group, * p<0.05, * p<0.01.
5, conclusion: LycospidineA has the effect obviously promoting oral ulcer healing.
Claims (3)
1. treatment or a preventing canker sore medicine, it is characterized in that, be made up of compound L ycospidineA and adjuvant, described compound L ycospidineA structure is as shown in formula I:
Formula I.
2. treat as claimed in claim 1 or preventing canker sore medicine, it is characterized in that, adjuvant is dextrin or starch.
3. treatment or the application of preventing canker sore medicine in treatment or preventing canker sore medicine as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510500362.1A CN105147676A (en) | 2015-08-14 | 2015-08-14 | Medicine for preventing or treating dental ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510500362.1A CN105147676A (en) | 2015-08-14 | 2015-08-14 | Medicine for preventing or treating dental ulcer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105147676A true CN105147676A (en) | 2015-12-16 |
Family
ID=54788962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510500362.1A Pending CN105147676A (en) | 2015-08-14 | 2015-08-14 | Medicine for preventing or treating dental ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105147676A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263423A (en) * | 2013-06-03 | 2013-08-28 | 南京正亮医药科技有限公司 | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
| CN104225346A (en) * | 2014-10-14 | 2014-12-24 | 张德信 | Chinese herbal preparation for treating hematuria and preparation method thereof |
-
2015
- 2015-08-14 CN CN201510500362.1A patent/CN105147676A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263423A (en) * | 2013-06-03 | 2013-08-28 | 南京正亮医药科技有限公司 | Application of myriberine A in preparation of medicaments for treating or preventing canker sores |
| CN104225346A (en) * | 2014-10-14 | 2014-12-24 | 张德信 | Chinese herbal preparation for treating hematuria and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| JIN-TANG CHENG 等: "Lycospidine A, a New Type of Lycopodium", 《ORGANIC LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585147B (en) | Application of Nitrosporeusines A in preparation of oral ulcer treatment or prevention medicines | |
| CN103462951B (en) | Application of scopariusins in preparation of medicine treating or preventing canker sore | |
| CN103599104B (en) | Application of Caesanines D in drug for treating or preventing dental ulcer | |
| CN103505464B (en) | The application of Phyllanthoid A in preparation treatment or preventing canker sore medicine | |
| CN103356653B (en) | The application of Chukrasone A in preparation treatment or preventing canker sore medicine | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN103638005B (en) | The application of Hippolachnin A in treatment or preventing canker sore medicine | |
| CN106344555A (en) | Application of Fistulains B in drugs for dental ulcer prevention or treatment | |
| CN103479624B (en) | Application of Racemosins A in preparation of oral ulcer treatment or prevention medicines | |
| CN105147676A (en) | Medicine for preventing or treating dental ulcer | |
| CN105412109A (en) | Application of Biscarpamontamine B in preparing drugs for treating or preventing dental ulcers | |
| CN105287543A (en) | Application of strynuxlines B to prepare medicines treating or preventing oral ulcer | |
| CN105232531A (en) | Application of Penifulvin A in preparing drugs for treating or preventing dental ulcers | |
| CN105434428A (en) | Applications of Volvalerelactones B in preparing drugs used for treating or preventing dental ulcer | |
| CN106491621A (en) | Friedolanostanes is preparing treatment or the application in preventing canker sore medicine | |
| CN103263423A (en) | Application of myriberine A in preparation of medicaments for treating or preventing canker sores | |
| CN102872056B (en) | Application of Gypensapogenin A to preparing drugs for treating or preventing canker sores | |
| CN102988382B (en) | Application of Houttuynoid C for preparing medicine for treating or preventing dental ulcer | |
| CN106265638A (en) | Linderolide H application in preparation treatment or preventing canker sore medicine | |
| CN102872060B (en) | Application of Gypensapogenin B to preparing drugs for treating or preventing canker sores | |
| CN106619604A (en) | Medicine for treating or preventing dental ulcer, and application of medicine | |
| CN103462998A (en) | Application of Neonectrolide A in preparing medicament for treating or preventing dental ulcer | |
| CN103961654B (en) | A kind of White staphylococcus sheet and preparation method thereof | |
| CN103393655A (en) | Application of Sarcaboside B to medicament for treatment and prevention of oral ulcer | |
| CN103356549A (en) | Application of Sarcaboside A in medicine for treating or preventing oral ulcer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151216 |
|
| WD01 | Invention patent application deemed withdrawn after publication |